Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. QCOM
5. IONS
6. AZN
7. NVS
8. ROIV
9. ORCL
10. AAPL

Go back to Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson Humphrey

October 16, 2017 11:16 AM EDT

SunTrust Robinson Humphrey raised its price target on Exelixis (NASDAQ: EXEL) to $35.00 (from $33.00) while maintaining a Buy rating.

... More